BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study

Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective stu...

Full description

Saved in:
Bibliographic Details
Published inAnnals of internal medicine Vol. 101; no. 4; p. 447
Main Authors Bakemeier, R F, Anderson, J R, Costello, W, Rosner, G, Horton, J, Glick, J H, Hines, J D, Berard, C W, DeVita, Jr, V T
Format Journal Article
LanguageEnglish
Published United States 01.10.1984
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.
AbstractList Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.
Author Glick, J H
DeVita, Jr, V T
Costello, W
Berard, C W
Anderson, J R
Bakemeier, R F
Horton, J
Hines, J D
Rosner, G
Author_xml – sequence: 1
  givenname: R F
  surname: Bakemeier
  fullname: Bakemeier, R F
– sequence: 2
  givenname: J R
  surname: Anderson
  fullname: Anderson, J R
– sequence: 3
  givenname: W
  surname: Costello
  fullname: Costello, W
– sequence: 4
  givenname: G
  surname: Rosner
  fullname: Rosner, G
– sequence: 5
  givenname: J
  surname: Horton
  fullname: Horton, J
– sequence: 6
  givenname: J H
  surname: Glick
  fullname: Glick, J H
– sequence: 7
  givenname: J D
  surname: Hines
  fullname: Hines, J D
– sequence: 8
  givenname: C W
  surname: Berard
  fullname: Berard, C W
– sequence: 9
  givenname: V T
  surname: DeVita, Jr
  fullname: DeVita, Jr, V T
BackLink https://www.ncbi.nlm.nih.gov/pubmed/6089632$$D View this record in MEDLINE/PubMed
BookMark eNo9kM1O5DAQhH1gxd_yBAipb1wI2J6QH27saBaQQINWiCtq2z0zhsSObCe7edh9FzKAOLX6q1J1qQ_YjvOOGDsW_LycyeKCcz7L8krUmeAiy7M8L3fY_jfdYwcxvm7XSla7bLfgVV3M5D77_2v-_PgIekOtTxsK2I2w8gHQDOg0Gbj1Zv1m3WkEYyNhpCugwRqaxA_jOhAmCmD6gMl6B34F2rddQ4kgUGtjnOjZty_2YbADNmeAzkBDMULy_6y2aYS0QQd_bdoAwsNyqhVobVty5_CHYt-kuA2fWsIC45TlYO59R9u7A8HSad_49Qg3wfcdxNSb8Sf7scIm0tHXPGRPvxdP89vsfnlzN7--z7So85TpqpRGFhyVKIymfKXkJWJZa13mUkkzUVVVxEVZ6hlXiqq8VrWQBpW5JCEP2clnbNerlsxLF2yLYXz5-rJ8B08EhSk
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.7326/0003-4819-101-4-447
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 6089632
Genre Research Support, U.S. Gov't, P.H.S
Comparative Study
Clinical Trial
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA 23318
– fundername: NCI NIH HHS
  grantid: CA 11083
– fundername: NCI NIH HHS
  grantid: CA 21115
GroupedDBID ---
..I
.55
.GJ
.XZ
08G
1CY
23M
2WC
354
36B
39C
3O-
3V.
4.4
53G
5GY
5RE
5RS
6J9
7RV
7X7
88E
8C1
8F7
8FI
8FJ
8G5
8R4
8R5
AAKAS
AAQOH
AAQQT
AARDX
AAWTL
AAYOK
ABBLC
ABCQX
ABJNI
ABOCM
ABPMR
ABUWG
ACBNA
ACGFO
ACGFS
ADBBV
ADZCM
AEGXH
AENEX
AERZD
AFCHL
AFFNX
AFKRA
AHJKT
AHMBA
AI.
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AQUVI
ASPBG
AVWKF
AZFZN
AZQEC
BCR
BCU
BEC
BENPR
BKEYQ
BKNYI
BLC
BPHCQ
BTJBQ
BVXVI
BZLQD
C1A
C45
CCPQU
CGR
CUY
CVF
DWQXO
E3Z
EBS
ECM
EIF
EJD
EMB
EMOBN
EX3
F5P
FEDTE
FYUFA
G8K
GNUQQ
GUQSH
H13
HMCUK
HVGLF
H~9
IH2
J5H
K-O
K9-
L7B
LPU
M0R
M0T
M1P
M2O
M5~
MV1
MVM
N4W
NAPCQ
NPM
OBH
OCB
OFXIZ
OGEVE
OHH
OHT
OVD
OVIDX
P2P
PCD
PQQKQ
PROAC
PSQYO
Q2X
RWL
RXW
S0X
SJFOW
SJN
SV3
TAE
TEORI
TPH
TR2
TWZ
UKHRP
UKR
VH1
VVN
WH7
WOQ
WOW
X6Y
X7M
XOL
YFH
YOC
YQJ
YYP
ZGI
ZXP
ZY1
~H1
ID FETCH-LOGICAL-c194t-c872d260ab16dce4fb25aa79cc742b2d16db88e0177c30bbe849b912dabd5e12
ISSN 0003-4819
IngestDate Sat Sep 28 08:35:12 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c194t-c872d260ab16dce4fb25aa79cc742b2d16db88e0177c30bbe849b912dabd5e12
PMID 6089632
ParticipantIDs pubmed_primary_6089632
PublicationCentury 1900
PublicationDate 1984-Oct
PublicationDateYYYYMMDD 1984-10-01
PublicationDate_xml – month: 10
  year: 1984
  text: 1984-Oct
PublicationDecade 1980
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Annals of internal medicine
PublicationTitleAlternate Ann Intern Med
PublicationYear 1984
SSID ssj0003828
Score 1.4894662
Snippet Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and...
SourceID pubmed
SourceType Index Database
StartPage 447
SubjectTerms Adult
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Blood Cell Count
Carmustine - administration & dosage
Carmustine - adverse effects
Clinical Trials as Topic
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Cyclophosphamide - adverse effects
Female
Gastrointestinal Diseases - chemically induced
Hematologic Diseases - chemically induced
Hodgkin Disease - drug therapy
Hodgkin Disease - pathology
Humans
Male
Mechlorethamine - administration & dosage
Mechlorethamine - adverse effects
Neoplasm Staging
Peripheral Nervous System Diseases - chemically induced
Prednisone - administration & dosage
Prednisone - adverse effects
Procarbazine - administration & dosage
Procarbazine - adverse effects
Random Allocation
Vinblastine - administration & dosage
Vinblastine - adverse effects
Vincristine - administration & dosage
Vincristine - adverse effects
Title BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study
URI https://www.ncbi.nlm.nih.gov/pubmed/6089632
Volume 101
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1La9tAEICXJKUll9JXSJ_ModCDo9SSVtaqt9SkNQEnobglt7C7WgVT2zKxXUr_a_9LZ_YhGSelj4sx0rJeez6PZmfnwdjrKtOKZyllt0sV8diISKmqispupaVOlOnZ3KrhaW_wmZ9cZBdb2ztrUUurpTrUP27NK_kfqeI1lCtlyf6DZJtJ8QK-R_niK0oYX_9Kxu_7X87PO_izT30elYu-bM71B3V5Zdtt5YtwEmM78fhOonbwFVmN1CZ8dd1YjzbOHK3pzjV1gyN_GkkijFysUL18s40C7NHDhJTlsv4-1mTRkyveZ8x1hme4PGr9MDWzQzopWE1c6AhZu8fS1mhAjVTPja8_fjbTriaU85G1tW9vlHseO0_m5GZwgPxqpmbsWzq3gctHNovHfZOTNkyyT0ku_vypcTd9qhc-D-hj6xWJC8Gb-LpW06cRF14dB03fjmj9GFZvc1f2c_N5kqe2A2YzGX4K7rijjdEoufnUItbrClRoyR9vbpT49ne22XYuSFefksfJWxOpSETo-khLcJWzaGFvb1nWLrvrJ9vYJllzafSA3ff7HDhy0D5kW2b2iN0bemE9Zj8tu7DOLiCOENgFz-6bBXhy30Hg1g70NELgFuoKArfQcHvQjAvUHgAyC8QsBGaBmAViFiQQsxCYBc8sTY6rBM8srDELgVmwzIJl9gkbfTge9QeRbzUS6bjgy0iLPClxay9V3Cu14ZVKMinzQuucJyop8aoSwuDjK9dpVykjeKGKOCmlKjMTJ3tsZ1bPzD6DuEq6ZcYLyUWXV3Eu89homZVFrFOOj8enbM_J5XLuyslceoE9-92N52y3JfwFu1PhH828RFN4qV5ZVn4BdoO5bw
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=BCVPP+chemotherapy+for+advanced+Hodgkin%27s+disease%3A+evidence+for+greater+duration+of+complete+remission%2C+greater+survival%2C+and+less+toxicity+than+with+a+MOPP+regimen.+Results+of+the+Eastern+Cooperative+Oncology+Group+study&rft.jtitle=Annals+of+internal+medicine&rft.au=Bakemeier%2C+R+F&rft.au=Anderson%2C+J+R&rft.au=Costello%2C+W&rft.au=Rosner%2C+G&rft.date=1984-10-01&rft.issn=0003-4819&rft.volume=101&rft.issue=4&rft.spage=447&rft_id=info:doi/10.7326%2F0003-4819-101-4-447&rft_id=info%3Apmid%2F6089632&rft_id=info%3Apmid%2F6089632&rft.externalDocID=6089632
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4819&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4819&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4819&client=summon